Immunovant
IMVT
142 hedge funds and large institutions have $904M invested in Immunovant in 2023 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 57 increasing their positions, 41 reducing their positions, and 16 closing their positions.
372% more call options, than puts
Call options by funds: $8.97M | Put options by funds: $1.9M
63% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 16
39% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 41
8% more funds holding
Funds holding: 132 → 142 (+10)
1.98% more ownership
Funds ownership: 42.75% → 44.73% (+2%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
8% less capital invested
Capital invested by funds: $980M → $904M (-$76.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$28.8M |
| 2 |
PA
Perceptive Advisors
New York
|
+$19.8M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$18.1M |
| 4 |
Millennium Management
New York
|
+$17.4M |
| 5 |
State Street
Boston,
Massachusetts
|
+$14.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$40M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$39.5M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$11.8M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$11.3M |
| 5 |
Walleye Capital
New York
|
-$9.48M |
IMVT Hedge Fund Activity: Q1 2023 in Review
142 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q1 2023, worth a combined $904M — down 7.8% from $980M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new IMVT positions and 16 closed out — a net gain of 10 holders — while 57 added to existing stakes and 41 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $28.8M. The largest seller was Eventide Asset Management, cutting an estimated $40M.
- 142 institutional investors held Immunovant (IMVT) as of Q1 2023, up from 132 in Q4 2022.
- Funds reported $904M of Immunovant stock for Q1 2023, down 7.8% quarter-over-quarter.
- 26 funds opened new Immunovant positions in Q1 2023 and 16 closed out, a net change of +10 holders.
- The largest Immunovant buyer in Q1 2023 was Fidelity Investments, an estimated $28.8M added.
- The largest Immunovant seller in Q1 2023 was Eventide Asset Management, an estimated $40M sold.
Based on aggregated 13F filings for Q1 2023.